Xenon Pharmaceuticals (XENE) Depreciation & Amortization (CF) (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Depreciation & Amortization (CF) of $587000.0 for Q1 2026, down 10.93% year-over-year from $659000.0 in Q1 2025, and down 3.93% quarter-over-quarter from $611000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $587000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $587000.0, down 10.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (down 6.15% YoY), and the FY2025 annual result was $2.5 million, down 0.66% from the prior year.
- Depreciation & Amortization (CF) eased to $587000.0 in Q1 2026 per XENE's latest filing, from $611000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $1.7 million in Q3 2023 and troughed at -$629000.0 in Q4 2023.
- A 5-year average of $538588.2 and a median of $602000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 384.36% in 2023 and fell as far as 312.5% in 2023.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $296000.0 in 2022, then sank by 312.5% to -$629000.0 in 2023, then jumped by 205.88% to $666000.0 in 2024, then retreated by 8.26% to $611000.0 in 2025, then fell by 3.93% to $587000.0 in 2026.
- Business Quant data shows XENE's Depreciation & Amortization (CF) at $587000.0 in Q1 2026, $611000.0 in Q4 2025, and $641000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | 587,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 587,000.00 |
| Mar 31, 2026 | 587,000.00 |
| Dec 31, 2025 | 611,000.00 |
| Dec 31, 2025 | 611,000.00 |
| Sep 30, 2025 | 641,000.00 |
| Sep 30, 2025 | 641,000.00 |
| Jun 30, 2025 | 632,000.00 |
| Jun 30, 2025 | 632,000.00 |
| Mar 31, 2025 | 659,000.00 |
| Mar 31, 2025 | 659,000.00 |
| Dec 31, 2024 | 666,000.00 |
| Dec 31, 2024 | 666,000.00 |
| Sep 30, 2024 | 667,000.00 |
| Sep 30, 2024 | 667,000.00 |
| Jun 30, 2024 | 641,000.00 |
| Jun 30, 2024 | 641,000.00 |
| Mar 31, 2024 | 586,000.00 |
| Mar 31, 2024 | 586,000.00 |
| Dec 31, 2023 | -629,000.00 |
| Dec 31, 2023 | -629,000.00 |